key: cord-0758726-gmmmvtoh
authors: Khoury, Emma; Nevitt, Sarah; Madsen, William Rohde; Turtle, Lance; Davies, Gerry; Palmieri, Carlo
title: Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis
date: 2022-05-09
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2022.10880
sha: 632de6236a737fbc9232a3bc2b6961d547aef6a1
doc_id: 758726
cord_uid: gmmmvtoh

IMPORTANCE: SARS-CoV-2 infection has been associated with more severe disease and death in patients with cancer. However, the implications of certain tumor types, treatments, and the age and sex of patients with cancer for the outcomes of COVID-19 remain unclear. OBJECTIVE: To assess the differences in clinical outcomes between patients with cancer and SARS-CoV-2 infection and patients without cancer but with SARS-CoV-2 infection, and to identify patients with cancer at particularly high risk for a poor outcome. DATA SOURCES: PubMed, Web of Science, and Scopus databases were searched for articles published in English until June 14, 2021. References in these articles were reviewed for additional studies. STUDY SELECTION: All case-control or cohort studies were included that involved 10 or more patients with malignant disease and SARS-CoV-2 infection with or without a control group (defined as patients without cancer but with SARS-CoV-2 infection). Studies were excluded if they involved fewer than 10 patients, were conference papers or abstracts, were preprint reports, had no full text, or had data that could not be obtained from the corresponding author. DATA EXTRACTION AND SYNTHESIS: Two investigators independently performed data extraction using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Meta-analysis was performed using a random-effects model. MAIN OUTCOMES AND MEASURES: The difference in mortality between patients with cancer and SARS-CoV-2 infection and control patients as well as the difference in outcomes for various tumor types and cancer treatments. Pooled case fatality rates, a random-effects model, and random-effects meta-regressions were used. RESULTS: A total of 81 studies were included, involving 61 532 patients with cancer. Among 58 849 patients with available data, 30 557 male individuals (52%) were included and median age ranged from 35 to 74 years. The relative risk (RR) of mortality from COVID-19 among patients with vs without cancer when age and sex were matched was 1.69 (95% CI, 1.46-1.95; P < .001; I(2) = 51.0%). The RR of mortality in patients with cancer vs control patients was associated with decreasing age (exp [b], 0.96; 95% CI, 0.92-0.99; P = .03). Compared with other cancers, lung cancer (RR, 1.68; 95% CI, 1.45-1.94; P < .001; I(2) = 32.9%), and hematologic cancer (RR, 1.42; 95% CI, 1.31-1.54; P < .001; I(2) = 6.8%) were associated with a higher risk of death. Although a higher point estimate was found for genitourinary cancer (RR, 1.11; 95% CI, 1.00-1.24; P = .06; I2 = 21.5%), the finding was not statistically significant. Breast cancer (RR, 0.51; 95% CI, 0.36-0.71; P < .001; I(2) = 86.2%) and gynecological cancer (RR, 0.76; 95% CI, 0.62-0.93; P = .009; I(2) = 0%) were associated with a lower risk of death. Chemotherapy was associated with the highest overall pooled case fatality rate of 30% (95% CI, 25%-36%; I(2) = 86.97%; range, 10%-100%), and endocrine therapy was associated with the lowest at 11% (95% CI, 6%-16%; I(2) = 70.68%; range, 0%-27%). CONCLUSIONS AND RELEVANCE: Results of this study suggest that patients with cancer and SARS-CoV-2 infection had a higher risk of death than patients without cancer. Younger age, lung cancer, and hematologic cancer were also risk factors associated with poor outcomes from COVID-19.

(((((cancer) OR (malignan*)) OR (tumour)) OR (neoplasm)) AND ((((2019-nCoV pneumonia) OR (SARS-CoV-2)) OR (Coronavirus)) OR (COVID-19))) AND ((solid) OR (haematolog*)) ("cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields] OR "malignan*" lower mortality rates in adjusted analysis (OR 0.72, 95% CI 0.53-0.98) compared to non-white Hispanic patients 42 . Hispanic patients did not have increased risk of mortality compared to non-Hispanic patients 41 . Non-white race was found to be significantly associated with hospitalisation and severe illness compared to white race 6, 20 . Asian ethnicity was associated with increased mortality [HR 3.73; 95% CI: 1.28-10.91] in adjusted analysis 43 .

There was variability with regards to the reported effect of stage of malignancy on outcomes with COVID- 19 

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

COVID-19 outcomes of patients with gynecologic cancer in New York City

A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy

Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies

Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center

COVID-19 outcomes in patients with hematologic disease

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)

Cancer patients affected by COVID-19: Experience from Milan

COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes. Indian journal of hematology & blood transfusion : an official journal of Indian Society of

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Determinants of COVID-19 disease severity in patients with cancer

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

Chemotherapy and COVID-19 Outcomes in Patients With Cancer

Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death

Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study

Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients

Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv : the preprint server for health sciences

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)

Covid-19 and cancer: Lessons learnt from a michigan hotspot

Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients

COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Early predictors of clinical outcomes of COVID-19 outbreak in

Extent of Prior Lung Irradiation and Mortality in COVID-19 Patients With a Cancer History

Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study